ABSTRACT
Objective:To systematically evaluate the clinical efficacy and safety of Xixian Tongshuan Capsules/Pills combined with Western medicine in treating cerebral infarction.Methods:All RCTs about Xixian Tongshuan Capsules/Pills combined with Western medicine in treating cerebral infarction were retrieved from CNKI, Wanfang Database, VIP database, PubMed and CBM. The search period was from the database establishment to December 31, 2021. Two researchers independently extracted the basic literature data and evaluated the methodological quality, then used RevMan5.4 software for meta-analysis.Results:Totally 9 articles were included, involving a total of 988 patients, including 505 cases in the observation group and 483 cases in the control group. Meta-analysis showed that the total effective rate of Xixian Tongshuan Capsules/Pills combined with Western medicine in treating cerebral infarction was higher than that of conventional Western medicine [ RR=1.20, 95% CI (1.13, 1.27), P<0.05]. At the same time, the effect of NIHSS score, Barthel score and FIB were better than those of conventional Western medicine [respectively: MD=-3.21, 95% CI (-4.45, -1.97), P<0.05; MD=11.83, 95% CI (10.66, 13.00), P<0.05; MD=-0.95, 95% CI (-1.36, -0.54), P<0.05]. After treatment with Xixian Tongshuan Capsules/Pills combined with Western medicine, the adverse reactions mainly included dizziness, nausea, indigestion, rash, facial blushing, etc. There was no statistically significant difference in safety between the two groups [ RR=1.50, 95% CI (0.75, 3.01), P>0.05]. Conclusions:Under the treatment of conventional Western medicine, the addition of Xixian Tongshuan Capsules/Pills can improve the clinical efficacy of cerebral infarction treatment, effectively improve the symptoms of neurological impairment, improve the ability of daily life, and promote the prognosis and recovery, and without increasing the incidence of adverse reactions. However, large sample and high quality studies are still needed to support the conclusion.
ABSTRACT
Objective To establish a preliminary evaluation system for gastrointestinal qi stagnation syndrome.Methods On the basis of the systematic evaluation of medical literature in the early stage of the research group,24 high-frequency items were subjected to Delphi method,the item indexes were determined through three rounds of expert consultation,and the proportion value of the indexes was determined by AHP,and the evaluation system of gastrointestinal qi stagnation syndrome was initially constructed.Results A total of 84 valid questionnaires were collected by three rounds of Delphi method,including 15 in the first round,32 in the second round and 37 in the third round.According to the statistics,16 items including distention(stuffy)or distending pain or moving pain(epigastric,abdominal,etc.),belching,borborygmus,flatus,etc.were selected.The order of the proportion of the first level indexes obtained by the analytic hierarchy process from high to low is:clinical symptoms,pulse,tongue;The proportion of secondary indicators from high to low is as follows:distention(stuffy)or distending pain or moving pain(epigastric,abdominal,etc.),pulse string,greasy fur,thin white fur,slippery pulse string,pulse sinking string,light red tongue,flatus,borborygmus,belching,induced or aggravated in case of emotional distress,hiccup,abdominal mass,anorexia,vomiting,belching and swallowing acid.Conclusion Delphi method and analytic hierarchy process have been used to study gastrointestinal qi stagnation syndrome,and an evaluation system has been preliminarily formed.The index structure is reasonable,targeted and has strong clinical practicability.
ABSTRACT
Objective To investigate the effectiveness and safety of intraoperative sac coiling embolization among patients who are athigh-risk developing type-Ⅱ endoleak after endovascular aortic repair (EVAR).Methods From Jan 2014 to Jan 2018,one hundred and twelve consecutive patients with infrarenal AAA were enrolled for this study,There were 76 patients undergoing standard EVAR (standard-group) and 36 patients doing aneurysmal sac coiling embolization (embo-group).Baseline characteristics,aneurysmal sac parameters,radiological intervention details and follow up results were recorded.Results Mean follow-up time was 25.9 m for embo-group.During follow-up period,no coils-related complications were noted and no type-Ⅱ endoleak associated secondary interventions were reported.A mean of (2.72 ± 1.16) coils (range 1-7) was used in the embo-group.The incidence of type Ⅱ endoleak was 30.3% (23/76) in standard-group and 11.1% (4/36) in embo-group(x2 =4.90,P =0.027).Logistic multivariate analysis revealed that the independent risk factors of type Ⅱ endoleak after endovascular aortic repair for high-risk patients were those EVAR without sac embolization and sac volume ≥ 128 cm3.In the subgroup analysis (sac volume≥ 128 cm3),the incidence of type-Ⅱ endoleak was lower in embo-group compared to standard-group (x2 =6.07,P =0.014).Conclusion Intraoperative sac coiling embolization in high-risk patients is safe and effective in prevention of type Ⅱ endoleak.This preventive effect is more significant with large sac aneurysm compared to small sac aneurysm.
ABSTRACT
Objective@#To investigate the effectiveness and safety of intraoperative sac coiling embolization among patients who are athigh-risk developing type-Ⅱ endoleak after endovascular aortic repair(EVAR).@*Methods@#From Jan 2014 to Jan 2018, one hundred and twelve consecutive patients with infra-renal AAA were enrolled for this study, There were 76 patients undergoing standard EVAR (standard-group)and 36 patients doing aneurysmal sac coiling embolization (embo-group). Baseline characteristics, aneurysmal sac parameters, radiological intervention details and follow up results were recorded.@*Results@#Mean follow-up time was 25.9 m for embo-group. During follow-up period, no coils-related complications were noted and no type-Ⅱ endoleak associated secondary interventions were reported. A mean of (2.72±1.16) coils (range 1-7) was used in the embo-group. The incidence of type Ⅱ endoleak was 30.3%(23/76) in standard-group and 11.1%(4/36) in embo-group(χ2=4.90, P=0.027). Logistic multivariate analysis revealed that the independent risk factors of type Ⅱ endoleak after endovascular aortic repair for high-risk patients were those EVAR without sac embolization and sac volume≥128 cm3. In the subgroup analysis (sac volume≥128 cm3), the incidence of type-Ⅱ endoleak was lower in embo-group compared to standard-group (χ2=6.07, P=0.014).@*Conclusion@#Intraoperative sac coiling embolization in high-risk patients is safe and effective in prevention of type Ⅱ endoleak. This preventive effect is more significant with large sac aneurysm compared to small sac aneurysm.
ABSTRACT
OBJECTIVE:To evaluate clinical efficacy of Shenling baizhu powder combined with aminosalicylic acid in the treatment of ulcerative colitis (UC),and to provide evidence-based reference in clinic.METHODS:Retrieved from PubMed,Cochrane library,CJFD,VIP,Wanfang database and CBM,randomized controlled trials (RCTs) about Shenling baizhu powder combined with aminosalicylic acid preparations (trial group) vs.aminosalicylic acid preparations alone (control group) in the treatment of UC were collected.Meta-analysis was performed by using Rev Man 5.2 statistical software afder data extraction and quality evaluation with Cochrane systematic evaluator manual 5.1.0.RESULTS:A total of 14 RCTs were included,involving 1 177 patients.Meta-analysis showed that total response rate of trial group was significantly higher than that of control group [OR=3.40,95% CI (2.44,4.74),P<0.001],while Sutherland DAI score [MD=-1.31,95% CI (-2.07,-0.56),P<0.001],the levels of TNF-α [SMD=-1.90,95%CI(-2.90,-0.90),P<0.001],IL-17[MD=-85.18,95%CI(-100.51,-69.85),P<0.001] and IL-23 [MD=-113.27,95%CI(-132.34,-94.21),P<0.001] in trial groups were significantly lower than control group,with statistical significance.CONCLUSIONS:Therapeutic efficacy of Shenling baizhu powder combined with aminosalicylic acid preparation is better than aminosalicylic acid preparation alone in the treatment of UC,and can significantly reduce Suthedand DAI and the levels of serum cytokines.
ABSTRACT
Objective To investigate the feasibility of high fat-introduced hyperlipeidemia model in male SD rat and study the time rule of molding .Methods 30 Male adult rats of SD Strain bred in the animal house of the institute were divided into 3 groups after 1 week adaptation , group 1:control group, normal diet;group 2:model 1 group, high fat high cholesterol diet;group 3:model 2 group, high fat high cholesterol diet .The period of experiment was 8 weeks.Food and water intake were measured everyday and body weight were measured every four days .Blood were collected by orbital venous at the end of fourth ,sixth,eighth week to test their serum lipid level .At the end of experiment ,animals were killed to collect liver and aorta tissue for HE stain .Results Compared with control group ,the food intake of model 1 was higher and model 2 was significant lower , water intake of model 2 was significant lower , the ratio of liver/weight of two model groups were significant heavier ,and weight of model groups were higher .High fat diet significantly increased TC levels of model groups at the end of fourth ,sixth week.The level of LDL-c in model 1 group were higher and the HDL-c were lower compared with control group .HE stain showed the livers of control group were regular ,arrangements of the liver cells were trim, dyeing present uniformity .The two model groups showed a large range of hepatocyte fatty change ,a few liver blood sinus were in congestion and infiltrated with inflammatory cells .Aorta HE stain showed no significant change among 3 groups.Conclusions The method of high fat-introduced hyperlipeidemia model in male SD rat is feasible and the model turned out to present hypercholesterolemia with severe fatty liver .On the other hand,levers of serum lipid increased within an increase—inter-adjustment—increase state .In the process of modeling ,how to overcome the symptom of anorexia and the state of cholesterol inter-adjustment in animals is the key to successfully establish hyperlipeidemia model .
ABSTRACT
Objective To investigate the clinical efficacy of simultaneous release of paclitaxel and cisplatin chemotherapy in treatment advanced cervical cancer.Methods 90 patients with advanced cervical cancer were randomly divided into control and experimental group,the experimental group was treated with paclitaxel and cisplatin concurrent radiotherapy and chemotherapy treatment,the control group was treated with 5-Fu,bleomycin and cisplatin for treatment.Results The clinical effective rate was 84.5%,which was higher than that of the control group (65.0%) ( P < 0.05 ) ; experimental group of patients whose bone marrow suppression and gastrointestinal disorders as well as opportunities arise severity were higher( P < 0.05 ) ; two groups of patients the clinical side effects appear no significant differences in case-times( P > 0.05 ).Conclusion The use of paclitaxel in advanced cervical cancer and cisplatin in patients with concurrent radiotherapy and chemotherapy treatment,which could effectively improve patient outcomes,improve patient survival.
ABSTRACT
[Objective] To assess the diagnostic criteria in literatures of blood-stasis syndrome based on evidence-based medicine. [Methods] The reports on blood-stasis syndrome published in the years of 1978 ~ 2002 were collected and evaluated according to the evidence-based medicine principles. Main outcomes include design method, sample screening, sample size, establishment of control group, randomization, blind method, criteria of diagnostic trials. [Results] In the reports collected, no gold standard and independent blind method were adopted, criteria of diagnostic trials such as sensitivity, specificity and likelihood ratio were incomplete and there was no descriptions of potential bias controlling. As for the literatures sharing the same diagnostic criteria of blood-stasis syndrome, their conclusion did not totally accord with each other. [Conclusion] Diagnostic criteria of blood - stasis syndrome are incomplete and need to be improved. The conclusion in published reports on diagnostic criteria of blood-stasis syndrome will be further verified.